Ken Song's Can­did li­cens­es a T cell en­gager from WuXi Bio

Can­did Ther­a­peu­tics is com­mit­ting up to $925 mil­lion for the rights to a trispe­cif­ic T cell en­gager can­di­date de­vel­oped by WuXi Bi­o­log­ics, fur­ther ex­pand­ing its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER